TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Oryzon Genomics SA ( (ES:ORY) ).
Oryzon Genomics S.A. has been granted a non-refundable aid of approximately €13.26 million from the Med4Cure project, the first Important Project of Common European Interest (IPCEI) in the healthcare sector. This funding will support the VANDAM project, covering 64% of its total budget, and will enable Oryzon to accelerate the clinical development of its epigenetic agents, vafidemstat and iadademstat, for treating rare diseases and hard-to-treat cancers, thereby strengthening its financial position and enhancing its mental health program.
More about Oryzon Genomics SA
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in epigenetics. The company focuses on developing personalized medicine approaches for rare and orphan diseases, particularly in the field of central nervous system disorders and neuroendocrine cancers.
Average Trading Volume: 1,428,253
Technical Sentiment Signal: Buy
Current Market Cap: €202.3M
Learn more about ORY stock on TipRanks’ Stock Analysis page.